<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773929</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-593_101</org_study_id>
    <nct_id>NCT00773929</nct_id>
  </id_info>
  <brief_title>Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer</brief_title>
  <official_title>A Multicenter Phase I Clinical and Pharmacokinetic Study of Oral TAK-593 in Subjects With Nonhematologic Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and toxicity profile of TAK-593 and&#xD;
      determine the maximum tolerated dose of TAK-593.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities of TAK-593 Pharmacokinetic parameters of TAK-593</measure>
    <time_frame>18-24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response outcomes including objective response and clinical benefit response.</measure>
    <time_frame>18-24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects each cohort. Escalate dose after safety evaluation of subjects in cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-593</intervention_name>
    <description>Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.&#xD;
Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥ 18 years of age diagnosed with advanced solid tumor cancer that failed to respond to&#xD;
             standard therapies and where no other treatment options are available.&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  Able to understand and follow study requirements&#xD;
&#xD;
          -  Subject or subject's legal representative signs a written, informed consent form prior&#xD;
             to beginning any study procedures.&#xD;
&#xD;
          -  Women who are post-menopausal for at least 1 year before screening or surgically&#xD;
             sterile&#xD;
&#xD;
          -  Women of childbearing potential agree to practice two effective methods of birth&#xD;
             control from the time of signing the informed consent form through 30 days after the&#xD;
             last dose of the study drug or agree to completely abstain from heterosexual&#xD;
             intercourse.&#xD;
&#xD;
          -  Men who agree to practice an effective method of birth control for the entire study&#xD;
             treatment period and through 30 days after the last dose of study drug or completely&#xD;
             agree to abstain from heterosexual intercourse.&#xD;
&#xD;
          -  Ability to swallow and retain oral medication&#xD;
&#xD;
          -  Meet study specific laboratory test standards for bone marrow function, liver&#xD;
             function, blood pressure, and renal function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cancer has spread to the brain&#xD;
&#xD;
          -  History of another cancer diagnosed or treated within the past 3 years.&#xD;
&#xD;
          -  Severe cardiovascular issues including heart attack within the past 6 months, unstable&#xD;
             angina or arrhythmias that require treatments.&#xD;
&#xD;
          -  Severe thyroid disease&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Arrhythmia issues&#xD;
&#xD;
          -  History of bleeding issues&#xD;
&#xD;
          -  Serious wounds, ulcers or bone fractures that do not heal&#xD;
&#xD;
          -  Subject is pregnant or breast feeding&#xD;
&#xD;
          -  Subject has illnesses or conditions that may affect their ability to participate in&#xD;
             the study&#xD;
&#xD;
          -  Subject participated in another clinical study/post marketing clinical study within 4&#xD;
             weeks prior to the start of this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>April 23, 2010</last_update_submitted>
  <last_update_submitted_qc>April 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Research Monitor</name_title>
    <organization>Millennium Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

